NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 58 filers reported holding NEUBASE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $32 | -40.7% | 172,628 | -39.5% | 0.00% | – |
| Q4 2022 | $54 | -100.0% | 285,221 | -0.8% | 0.00% | – |
| Q3 2022 | $114,000 | -54.6% | 287,386 | +20.2% | 0.00% | – |
| Q2 2022 | $251,000 | -37.9% | 239,131 | +11.3% | 0.00% | – |
| Q1 2022 | $404,000 | +17.4% | 214,838 | +75.5% | 0.00% | – |
| Q4 2021 | $344,000 | -75.6% | 122,386 | -68.7% | 0.00% | -100.0% |
| Q3 2021 | $1,412,000 | -30.6% | 391,193 | -7.9% | 0.00% | -33.3% |
| Q2 2021 | $2,035,000 | +40.5% | 424,851 | +116.9% | 0.00% | +50.0% |
| Q1 2021 | $1,448,000 | -50.9% | 195,878 | -53.6% | 0.00% | -33.3% |
| Q4 2020 | $2,952,000 | -30.1% | 422,378 | -24.1% | 0.00% | -25.0% |
| Q3 2020 | $4,226,000 | -46.3% | 556,732 | -37.9% | 0.00% | -42.9% |
| Q2 2020 | $7,868,000 | +189.7% | 896,078 | +134.9% | 0.01% | +133.3% |
| Q1 2020 | $2,716,000 | +6.8% | 381,478 | +8.0% | 0.00% | +50.0% |
| Q4 2019 | $2,543,000 | +97.9% | 353,202 | +37.2% | 0.00% | +100.0% |
| Q3 2019 | $1,285,000 | – | 257,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenlight Capital | 2,027,027 | $14,169,000 | 0.85% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 103,500 | $723,000 | 0.55% |
| Sio Capital Management, LLC | 293,699 | $2,053,000 | 0.42% |
| GSA CAPITAL PARTNERS LLP | 121,389 | $849,000 | 0.14% |
| Frontier Wealth Management LLC | 145,000 | $1,014,000 | 0.08% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $2,174,000 | 0.06% |
| Oak Grove Capital LLC | 19,175 | $134,000 | 0.04% |
| PREMIER ASSET MANAGEMENT LLC | 14,977 | $105,000 | 0.02% |
| Trexquant Investment LP | 15,479 | $108,000 | 0.01% |
| PILLAR PACIFIC CAPITAL MANAGEMENT LLC | 19,800 | $138,000 | 0.01% |